Quantitative Systematic Strategies LLC purchased a new stake in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the second quarter, Holdings Channel reports. The firm purchased 49,852 shares of the biopharmaceutical company’s stock, valued at approximately $751,000.
Several other institutional investors have also made changes to their positions in CLVS. Fox Run Management L.L.C. bought a new position in shares of Clovis Oncology during the second quarter valued at $154,000. CIBC World Markets Inc. boosted its position in shares of Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 850 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Clovis Oncology during the first quarter valued at $233,000. Kazazian Asset Management LLC bought a new position in shares of Clovis Oncology during the first quarter valued at $282,000. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Clovis Oncology by 46.9% in the second quarter. Candriam Luxembourg S.C.A. now owns 47,000 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 98.46% of the company’s stock.
Clovis Oncology Inc. (NASDAQ:CLVS) traded up 1.778% on Thursday, reaching $33.261. The company’s stock had a trading volume of 1,504,409 shares. The stock’s market capitalization is $1.28 billion. The firm has a 50 day moving average price of $30.54 and a 200 day moving average price of $18.97. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $109.18.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same quarter in the previous year, the firm earned ($2.10) EPS. On average, equities analysts anticipate that Clovis Oncology Inc. will post ($9.25) EPS for the current year.
Several research analysts have recently weighed in on CLVS shares. SunTrust Banks Inc. boosted their target price on Clovis Oncology from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, September 23rd. Zacks Investment Research cut Clovis Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, October 4th. Credit Suisse Group AG restated an “outperform” rating and set a $41.00 target price on shares of Clovis Oncology in a report on Monday. Piper Jaffray Cos. restated a “neutral” rating and set a $14.00 target price on shares of Clovis Oncology in a report on Thursday, August 25th. Finally, Janney Montgomery Scott cut Clovis Oncology from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $35.00 to $36.00 in a report on Wednesday, September 21st. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $36.39.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.